8-K

$SYK · Stryker Corporation

October 29, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Stryker reported third quarter 2026 net sales of $6.5 billion, up 7.7% on both a reported and organic basis. MedSurg and Neurotechnology sales rose 9.2% reported and 9.1% organic, while Orthopaedics sales increased 5.7% reported and 5.9% organic. Reported operating income margin was 15.9%, and adjusted operating income margin increased 60 basis points to 26.2%. Reported earnings per share decreased 11.7% to $1.96, while adjusted earnings per share increased 10.3% to $3.52. The company said the quarter reflected good overall performance but fell short of its expectations.

Reported net earnings were $753 million, down 12.3%, and included charges for acquisition and integration activities, amortization of purchased intangibles, restructuring, impairments, regulatory and legal matters, and other items. Adjusted net earnings were $1.4 billion, up 10.1%. Stryker repurchased $1.0 billion of common stock during the quarter, and in October 2026 its board approved a $3.0 billion increase to the existing share repurchase program.

For full-year 2026, Stryker updated its guidance to expect organic net sales growth of 6.5% to 7.0% and adjusted earnings per diluted share of $14.80 to $14.90. The sales guidance includes a modestly positive pricing impact, and foreign exchange is expected to have a slightly favorable impact if rates hold near current levels.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →